LITTLE GREEN PHARMA LIMITED (LGP)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
LGP - LITTLE GREEN PHARMA LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -1.04
Index:
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -1.04
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.13
24 Apr |
OPEN $0.13 |
HIGH $0.14 |
66,623 LOW $0.13 |
-0.005| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
| Title | 2018 | 2019 | 2020 | 2022 | 2023 |
|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | -3.4 |
| DPS All | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | 19.9 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | 27.6 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | -6.9 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | -43.09 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2018 | 2019 | 2020 | 2022 | 2023 |
|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | -10.85 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | -10.25 % |
| Return on Assets | xxx | xxx | xxx | xxx | -8.80 % |
| Return on Equity | xxx | xxx | xxx | xxx | -10.85 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | -15.58 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | -8.8 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2018 | 2019 | 2020 | 2022 | 2023 |
|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | 7 M |
| Long Term Debt | xxx | xxx | xxx | xxx | 5 M |
| Total Debt | xxx | xxx | xxx | xxx | 12 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | 12 M |
| Price To Book Value | xxx | xxx | xxx | xxx | 0.65 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2018 | 2019 | 2020 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | 4.9 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | 24.82 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | 12 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | 22 M |
| Research & Development | xxx | xxx | xxx | xxx | 7 M |
| Investments - Total | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
LGP STOCK CHART
FNArena News on LGP
| 1 |
Australian Broker Call *Extra* Edition – Apr 22, 2024Apr 22 2024 - Daily Market Reports |
| 2 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
| 3 |
Australian Broker Call *Extra* Edition – Nov 09, 2023Nov 09 2023 - Daily Market Reports |
| 4 |
Breaking Boundaries: Medical PsychedelicsAug 21 2023 - Small Caps |
| 5 |
Australian Broker Call *Extra* Edition – May 08, 2023May 08 2023 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |
| 2 |
The Power Of New Weight-Loss DrugsApr 03 2024 - International |
| 3 |
Dr Boreham’s Crucible: Neuren PharmaceuticalsMar 11 2024 - Small Caps |
| 4 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
| 5 |
Transformational Trial Results For Neuren PharmaceuticalsDec 20 2023 - Small Caps |
| 6 |
Dr Boreham’s Crucible: ImugeneDec 11 2023 - Small Caps |
| 7 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
| 8 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
| 9 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |
| 10 |
Dr Boreham’s Crucible: Cleo DiagnosticsAug 30 2023 - Small Caps |